The Directory of Pharma Companies and News


Reneuron logo
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need. ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments. The Company’s therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for the blindness-causing disease, retinitis pigmentosa, is about to commence clinical development in the US. ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting a range of cancers. ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at

Reneuron News

2016-02-23ReNeuron relocates to South Wales (PDF)
2016-02-23ReNeuron announces first patient treated in US Phase I/II clinical trial in blindness-causing disease, retinitis pigment... (PDF)
2016-02-23BBC Breakfast News Interview : Patient in ReNeuron Phase II clinical trial (PDF)
2016-02-23BBC News: Stem cells used in ReNeuron Phase II stroke treatment (PDF)
2016-02-23BBC Breakfast interviews patient in ReNeuron’s Phase II stroke clinical trial (PDF)
2016-02-23Retinitis pigmentosa Phase I/II clinical trial update and Notice of US Key Opinion Leader event (PDF)
2016-02-23Preliminary Results for the Year Ended 31 March 2016 (PDF)
2016-02-23Publication of positive pre-clinical data from retinal stem cells (PDF)
2016-02-01ReNeuron receives notice of grant of key US patent on its cell cryopreservation technology (PDF)
2016-01-11ReNeuron wins major UK grant to advance its exosome nanomedicine platform (PDF)
2015-12-17ReNeuron establishes Scientific Advisory Board (PDF)
2015-12-07Interim Results for the six months ended 30 September 2015 (PDF)
2015-12-07Webcast of 2016 Interim Results Presentation (PDF)
2015-12-07Webcast of Interim Results Presentation for 6 months to 30 September 2015 (PDF)
2015-12-04Non-executive Director appointment (PDF)
2015-09-24AGM Trading Update (PDF)
2015-09-24CEO presents at the 2015 Stem Cell meeting on the MESA (PDF)
2015-08-26Posting of Annual Report and Accounts and Notice of AGM (PDF)
2015-08-26N+1 Singer maintain Buy recommendation & increase target price by 61% to 10p (PDF)
2015-08-21Result of General Meeting (PDF)
2015-07-29Publication of Circular and Notice of General Meeting (PDF)
2015-07-10ReNeuron announces proposed Placing to raise £68.4 million and Notice of General Meeting (PDF)
2015-07-10Preliminary Results for the Year Ended 31 March 2015 (PDF)
2015-06-22ReNeuron announces research collaboration with Benitec Biopharma using exosomes as delivery system for gene silencing in... (PDF)
2015-06-11ReNeuron makes further senior management appointments (PDF)
2015-05-22FDA grants Fast Track designation to ReNeuron’s retinitis pigmentosa cell therapy candidate (PDF)
2015-05-05FDA gives ReNeuron approval to start a Phase I/II clinical trial in the US in retinitis pigmentosa (PDF)
-0001-11-30Notification of Interim Results (PDF)
Brought to you by - Latest Jobs in Pharma
Brought to you by - Latest Jobs in Pharma.